Artal Group’s Ascendis Pharma A/S ASND Stock Holding History

Artal Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-101,100	Closed	-$13.8M	–	11
2024 Q2	$13.8M	Buy	+101,100	New	+$13.8M	0.35%	33
2020 Q3	–	Sell	-65,000	Closed	-$9.61M	–	139
2020 Q2	$9.61M	Sell	65,000 -35,000	-35%	-$4.81M	0.27%	72
2020 Q1	$11.3M	Hold	100,000	–	–	0.48%	42
2019 Q4	$13.9M	Sell	100,000 -50,000	-33%	-$5.55M	0.54%	32
2019 Q3	$14.4M	Hold	150,000	–	–	0.58%	36
2019 Q2	$17.3M	Buy	150,000 +25,000	+20%	+$2.99M	0.7%	30
2019 Q1	$14.7M	Buy	+125,000	New	+$10.9M	0.6%	38

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Artal Group's ASND Position: Q3 2024 in Review

Artal Group sold out of Ascendis Pharma A/S (ASND) in Q3 2024, closing a stake of 101,100 shares — an estimated $13.8M sold.

Artal Group first reported a position in ASND in Q1 2019 and held it in 7 quarters. The position peaked at $17.3M in Q2 2019. 219 funds tracked by Wall St. Rank hold ASND as of Q3 2024.

Artal Group reported no remaining Ascendis Pharma A/S position as of Q3 2024 after selling out during the quarter.
Artal Group sold 101,100 Ascendis Pharma A/S shares in Q3 2024, an estimated $13.8M.
Artal Group first reported a position in Ascendis Pharma A/S in Q1 2019 and held it in 7 quarters.
Artal Group's Ascendis Pharma A/S position peaked at $17.3M in Q2 2019.
219 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.